CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
(TPC) in participants with advanced/metastatic gastroesophageal adenocarcinoma. The primary hypothesis of this study is sacituzumab tirumote...
Phase 3
Marietta, Georgia, United States and 152 other locations
The purpose of this study is to compare overall survival of quemliclustat, nab-paclitaxel and gemcitabine versus placebo, nab-paclitaxel and gemcitab...
Phase 3
Atlanta, Georgia, United States and 53 other locations
participants with platinum-resistant ovarian carcinoma, endometrial adenocarcinoma, and urothelial carcinoma based on Acrivon's OncoSignatur...
Phase 1, Phase 2
Atlanta, Georgia, United States and 66 other locations
and safety of AZD0901 compared to Investigator's choice of therapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma...
Phase 3
Atlanta, Georgia, United States and 182 other locations
unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. Why was this study being done? SPOTLIGHT was a new clinical ...
Phase 3
Newnan, Georgia, United States and 219 other locations
The study will compare the efficacy and safety of pembrolizumab plus trastuzumab in combination with standard of care (SOC) chemotherapy versus trast...
Phase 3
Newnan, Georgia, United States and 191 other locations
Zolbetuximab is being studied as a treatment for people with pancreatic cancer. Most people with pancreatic cancer have a protein called Claudin 18.2...
Phase 2
Newnan, Georgia, United States and 135 other locations
This is a Phase 2, multicenter, open-label, 3-arm, randomized, parallel group study to evaluate the efficacy and safety of TTX-030 with or without bu...
Phase 2
Atlanta, Georgia, United States and 63 other locations
This study is open to adults with advanced cancer of the colon, rectum, stomach, or pancreas, that is the cancer cannot be removed by surgery or has...
Phase 1
Atlanta, Georgia, United States and 4 other locations
This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody ta...
Phase 1
Atlanta, Georgia, United States and 33 other locations
Clinical trials
Research sites
Resources
Legal